Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Triple Negative Breast Neoplasms × ALT-803 × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Leukemia, Myeloid, Acute 3 Carcinoma, Merkel Cell 3 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Uterine Cervical Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Platinum-resistant Ovarian Cancer 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Microsatellite Instability 1 Melanoma 1 Lymphoma, B-Cell 1 Glioblastoma 1 Colorectal Neoplasms 1 Castration Resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1

Interventions

Carboplatin 69 Paclitaxel 56 pembrolizumab 54 Cyclophosphamide 37 Capecitabine 32 Doxorubicin 27 130-nm albumin-bound paclitaxel 26 Albumin-Bound Paclitaxel 24 Taxes 23 Gemcitabine 18 Bevacizumab 18 atezolizumab 17 olaparib 16 Docetaxel 16 Epirubicin 15 Cisplatin 15 eribulin 13 sacituzumab govitecan 12 durvalumab 12 camrelizumab 12 toripalimab 11 Drug Therapy 11 liposomal doxorubicin 8 apatinib 8 Trastuzumab 8 talazoparib 7 Specimen Handling 7 Radiotherapy 7 Magnetic Resonance Spectroscopy 7 tislelizumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡